Problem

Keylika is targeting iron deficiency and iron-deficiency anemia, a widespread but underserved condition caused by inadequate intake, poor absorption, blood loss, or underlying diseases. The company cites roughly 1.6 billion affected people worldwide, more than 30 million in the US, and an estimated $17 billion US market. Its initial “killer” use case is moderate-to-severe iron deficiency in women of child-bearing age, particularly those affected by menorrhagia, for whom effective iron replacement is often difficult to tolerate or absorb.

The current treatment trade-off is stark. Oral iron is inexpensive and convenient but often has low bioavailability, causes gastrointestinal side effects such as nausea, constipation, stomach discomfort, and diarrhea, and can lead to poor adherence; some patients do not absorb it adequately at all. IV iron is more effective for rapid repletion but is invasive, more expensive, requires an infusion facility or hospitalization, and carries a risk of hypersensitivity reactions. Keylika is trying to address the resulting gap between tolerability, convenience, efficacy, and cost.

Product / Service

Keylika is developing NistuFe, a prescription iron product built around its new small-molecule iron complex, KYLK01. The company’s public descriptions have evolved from a wearable transdermal skin patch to a newer resorbable buccal patch: the latter adheres to the inner cheek, dissolves in saliva in less than an hour, and delivers iron through the highly vascularized oral mucosa directly into systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism. The company describes the delivery technology as KEYPaxtek™ and positions it as a self-administered, non-injectable alternative to oral and IV iron.

The intended benefit is to combine the convenience of oral treatment with the systemic absorption and efficacy associated with parenteral iron, while avoiding oral gastrointestinal side effects and the cost, time, and clinical burden of infusions. More broadly, Keylika is building a drug-discovery and delivery platform: its mixed-ligand metallodrug synthesis technology is paired with formulation and micro- or nanotechnology-based delivery methods to create drugs for hematology, pain and inflammation, metabolic disease, infectious disease, oncology, and potentially other hard-to-deliver molecules. Evidence reported so far is preclinical, including efficacy and safety signals in iron-deficient rodents and hamsters rather than human clinical results.

Market

Keylika competes in drug delivery, hematology, and therapeutics, initially within the large iron-deficiency anemia treatment market. Its practical competitors are established oral iron supplements and IV iron products, including Injectafer/Ferinject and Monofer, as well as other prescription IV therapies such as Feraheme. Keylika’s differentiation is not a wholly new disease market but a proposed new route and formulation intended to occupy the space between inexpensive but poorly tolerated oral treatment and effective but costly, inconvenient IV treatment. The company also presents its buccal platform as potentially applicable to peptides, hormones, and other molecules with poor oral bioavailability.

Keylika remains an early-stage, pre-commercial biotech rather than an approved-product company. It was a Y Combinator Summer 2022 company and is described as active and early stage; more recent company-directory material reports completed preclinical testing and $3.7 million in non-dilutive funding, while a 2025 biotech showcase reported a pilot deal with a biopharma major to advance a hematology asset through preclinical studies. The latest reported milestones point toward additional preclinical work, first-in-human studies, and eventual FDA submissions, and the evidence gathered here does not show regulatory approval, human clinical data, product sales, or disclosed revenue.